Alberto Delaidelli

This study identifies AHCY as a key driver of epigenetic and metabolic reprogramming in ZFTA-RELA ependymomas, revealing its role in promoting tumor growth through pyrimidine synthesis and asparagine dependency.

This study shows HSPD1 enhances MYCN expression and tumorigenesis in neuroblastoma by supporting mitochondrial translation and proteostasis.

The paper identifies ependymomas as originating from the pre-neural crest/roof plate lineage using single-cell transcriptomics and lineage tracing.

This study identifies GALE as a key regulator of glycoproteome remodelling in RAS-driven cancer, showing its role in sialylation and tumorigenicity.

This study shows that EIF4EBP1 is upregulated by MYC in medulloblastoma and linked to poorer patient survival.

This study uses spatial transcriptomics to analyze aSyn pathology in mice, revealing metabolic and circadian disruptions at different stages of disease progression.

This study shows eEF2K is critical for the DNA damage response to cisplatin, promoting p53 activation and DNA repair depending on damage severity.

The paper identifies four immune clusters in pediatric nervous system tumors using RNA-seq data and validates them with multiple methods, highlighting the need for personalized immunogenomic profiling.

The paper shows that α-synuclein pathology in Parkinson's disease activates the NRF2 anti-oxidant response, suggesting it could be a therapeutic target.